alendronate and Low Bone Density studies

alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.

Research Excerpts

Excerpt	Relevance	Reference
" We aimed to determine the effect of alendronate on plasma glucose, insulin indices of postmenopausal women with prediabetes and osteopenia."	9.30	Alendronate improves fasting plasma glucose and insulin sensitivity, and decreases insulin resistance in prediabetic osteopenic postmenopausal women: A randomized triple-blind clinical trial. ( Amini, M; Aminorroaya Yamini, S; Aminorroaya, A; Feizi, A; Hadi Alijanvand, M; Kachuei, A; Karimi Fard, M; Karimifar, M; Salamat, MR, 2019)
"A hundred and sixty patients with early, active rheumatoid arthritis (RA) received methotrexate, intra-articular betamethasone and ciclosporin /placebo-ciclosporin."	9.19	Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. ( Abrahamsen, B; Andersen, LS; Ellingsen, T; Hansen, I; Hansen, MS; Hetland, ML; Hyldstrup, L; Hørslev-Petersen, K; Jensen, TW; Junker, P; Jurik, AG; Langdahl, B; Lauridsen, UB; Lindegaard, H; Lottenburger, T; Pedersen, JK; Pødenphant, J; Skjødt, H; Stengaard-Petersen, K; Svendsen, AJ; Tarp, U; Vestergaard, A; Zerahn, B; Østergaard, M, 2014)
"To evaluate the efficacy and safety of alendronate for the treatment of osteoporosis/osteopenia secondary to hyperthyroidism."	9.16	[Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism]. ( Shen, FX; Yang, LJ; Zhang, HL; Zheng, JC, 2012)
"Oral alendronate at a dose of 1 mg/kg/week for the treatment of osteopenia in children with cerebral palsy was found to be safe and effective."	9.16	Osteopenia in children with cerebral palsy can be treated with oral alendronate. ( Akin, R; Karacalioglu, AO; Karaoglu, A; Paksu, MS; Polat, A; Unay, B; Vurucu, S; Yesilyurt, O, 2012)
"The comparative effects of alendronate and alfacalcidol on bone mineral density (BMD) and bone turnover have already been established in postmenopausal women with osteoporosis."	9.14	Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures. ( Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M, 2009)
"Alendronate, vitamin D, and calcium are safe and potentially useful in the treatment of osteopenia/osteoporosis associated with HIV infection."	9.11	Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. ( Claxton, SA; Hoffmann, ME; Mondy, K; Powderly, WG; Royal, M; Stoneman, JS; Tebas, P; Yarasheski, KH, 2005)
"The current study was undertaken to investigate the effect of alendronate on bone mineral density (BMD), bone metabolism markers, and serum bone-resorbing cytokines in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis."	9.11	Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis. ( Christoforidou, A; Eliopoulos, GD; Malliaraki, N; Margioris, AN; Miliaki, M; Papadaki, HA; Pontikoglou, C; Psyllaki, M; Tsatsanis, C, 2004)
"A retrospective study was performed to evaluate the outcome of alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures."	7.83	Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures. ( Iwamoto, J; Uzawa, M, 2016)
"Treatment with once-weekly 70 mg alendronate significantly improved the BMD at the lumbar spine and femoral neck in patients with prostate cancer with severe osteopenia or osteoporosis and on ADT, and significantly decreased the risk of femoral neck fracture."	7.75	Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. ( Cecchini, L; Encabo, G; Morote, J; Orsola, A; Placer, J; Planas, J; Raventós, C; Salvador, C; Trilla, E, 2009)
"We describe a case of collapsing focal segmental glomerulosclerosis and severe kidney dysfunction in a liver transplant recipient after the initiation of alendronate for osteopenia."	7.74	Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. ( Djamali, A; Musat, A; Myers, J; Pascual, J; Samaniego, M; Tome, S; Torrealba, J, 2007)
") infusion of 5 mg alendronate was studied in ten patients with Paget's disease, six patients with primary hyperparathyroidism and ten osteopenic postmenopausal women."	7.69	Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. ( Adami, S; Bertoldo, F; Braga, B; Dorizzi, R; Gatti, D; Locascio, V; Mian, M; Rossini, M; Zamberlan, N, 1994)
"Osteopenia is a serious medical complication of anorexia nervosa, with no known effective treatment."	6.71	Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. ( Carey, D; Golden, NH; Hertz, S; Iglesias, EA; Jacobson, MS; Meyer, W; Schebendach, J; Shenker, IR, 2005)
"Losartan treatment, which lowers TGFβ signaling and restores aortic wall integrity in mice with mild MFS, did not mitigate bone loss in Fbn1(mgR/mgR) mice even though it ameliorated vascular disease."	5.36	Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. ( Carta, L; Cook, JR; Dietz, HC; Lee-Arteaga, S; Nistala, H; Ramirez, F; Rifkin, AN; Rifkin, DB; Siciliano, G; Smaldone, S, 2010)
"In this small study in children and adolescents perinatally infected with HIV with low LS BMD, 48 weeks of alendronate was well-tolerated, showed no safety concerns, and significantly improved LS and whole body BMD compared to participants on vitamin D/calcium supplementation and exercise alone."	5.34	Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age. ( Amaral, FR; Benson, J; Ferreira, F; Gaur, A; George, K; Gordon, C; Hazra, R; Jacobson, DL; Lindsey, JC; Pagano-Therrien, J; Siberry, GK; Spiegel, H, 2020)
" We aimed to determine the effect of alendronate on plasma glucose, insulin indices of postmenopausal women with prediabetes and osteopenia."	5.30	Alendronate improves fasting plasma glucose and insulin sensitivity, and decreases insulin resistance in prediabetic osteopenic postmenopausal women: A randomized triple-blind clinical trial. ( Amini, M; Aminorroaya Yamini, S; Aminorroaya, A; Feizi, A; Hadi Alijanvand, M; Kachuei, A; Karimi Fard, M; Karimifar, M; Salamat, MR, 2019)
"A hundred and sixty patients with early, active rheumatoid arthritis (RA) received methotrexate, intra-articular betamethasone and ciclosporin /placebo-ciclosporin."	5.19	Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. ( Abrahamsen, B; Andersen, LS; Ellingsen, T; Hansen, I; Hansen, MS; Hetland, ML; Hyldstrup, L; Hørslev-Petersen, K; Jensen, TW; Junker, P; Jurik, AG; Langdahl, B; Lauridsen, UB; Lindegaard, H; Lottenburger, T; Pedersen, JK; Pødenphant, J; Skjødt, H; Stengaard-Petersen, K; Svendsen, AJ; Tarp, U; Vestergaard, A; Zerahn, B; Østergaard, M, 2014)
"To evaluate the efficacy and safety of alendronate for the treatment of osteoporosis/osteopenia secondary to hyperthyroidism."	5.16	[Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism]. ( Shen, FX; Yang, LJ; Zhang, HL; Zheng, JC, 2012)
"Oral alendronate at a dose of 1 mg/kg/week for the treatment of osteopenia in children with cerebral palsy was found to be safe and effective."	5.16	Osteopenia in children with cerebral palsy can be treated with oral alendronate. ( Akin, R; Karacalioglu, AO; Karaoglu, A; Paksu, MS; Polat, A; Unay, B; Vurucu, S; Yesilyurt, O, 2012)
"The comparative effects of alendronate and alfacalcidol on bone mineral density (BMD) and bone turnover have already been established in postmenopausal women with osteoporosis."	5.14	Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures. ( Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M, 2009)
"The current study was undertaken to investigate the effect of alendronate on bone mineral density (BMD), bone metabolism markers, and serum bone-resorbing cytokines in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis."	5.11	Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis. ( Christoforidou, A; Eliopoulos, GD; Malliaraki, N; Margioris, AN; Miliaki, M; Papadaki, HA; Pontikoglou, C; Psyllaki, M; Tsatsanis, C, 2004)
" All patients received vitamin D and calcium supplementation before and after LT, those with osteopenia or osteoporosis prior to LT were additionally treated with alendronate following LT."	5.11	Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. ( Eichler, D; Finkenstedt, G; Graziadei, IW; Koenigsrainer, A; Margreiter, R; Millonig, G; Muehllechner, P; Pfeiffer, KP; Vogel, W, 2005)
"Alendronate, vitamin D, and calcium are safe and potentially useful in the treatment of osteopenia/osteoporosis associated with HIV infection."	5.11	Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. ( Claxton, SA; Hoffmann, ME; Mondy, K; Powderly, WG; Royal, M; Stoneman, JS; Tebas, P; Yarasheski, KH, 2005)
"We have found 11 cases of BRONJ in our hospital: 4 women taking oral alendronate or risendronate for osteoporosis and 7 cancer patients treated with intravenous zolendronic acid."	4.88	[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces]. ( Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A, 2012)
"Three completed randomised-controlled studies examined the role of alendronate in patients with HIV and osteopenia or osteoporosis."	4.84	Interventions for the treatment of decreased bone mineral density associated with HIV infection. ( Lin, D; Rieder, MJ, 2007)
"A retrospective study was performed to evaluate the outcome of alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures."	3.83	Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures. ( Iwamoto, J; Uzawa, M, 2016)
"Treatment with once-weekly 70 mg alendronate significantly improved the BMD at the lumbar spine and femoral neck in patients with prostate cancer with severe osteopenia or osteoporosis and on ADT, and significantly decreased the risk of femoral neck fracture."	3.75	Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. ( Cecchini, L; Encabo, G; Morote, J; Orsola, A; Placer, J; Planas, J; Raventós, C; Salvador, C; Trilla, E, 2009)
"We describe a case of collapsing focal segmental glomerulosclerosis and severe kidney dysfunction in a liver transplant recipient after the initiation of alendronate for osteopenia."	3.74	Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. ( Djamali, A; Musat, A; Myers, J; Pascual, J; Samaniego, M; Tome, S; Torrealba, J, 2007)
"Patients were eligible for inclusion if they had osteoporosis or osteopenia and demonstrated a decline in BMD during the preceding year while taking stable doses of alendronate or risedronate, plus supplemental calcium and vitamin D."	3.74	Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients. ( Adams, JS; Geller, JL; Hu, B; Mirocha, J; Reed, S, 2008)
"Treatment with alendronate was associated with significantly greater improvements in lumbar spine BMD within one year in breast cancer survivors when compared with treatment with cyclic etidronate or calcium and vitamin D."	3.73	Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis? ( Adachi, JD; Boulos, P; Brown, JP; Goldsmith, CH; Hanley, DA; Ioannidis, G; Josse, RG; Kouroukis, T; Murray, TM; Olszynski, WP; Papaioannou, A; Petrie, A; Sawka, AM; Sebaldt, RJ; Tenenhouse, A; Thabane, L, 2005)
") infusion of 5 mg alendronate was studied in ten patients with Paget's disease, six patients with primary hyperparathyroidism and ten osteopenic postmenopausal women."	3.69	Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. ( Adami, S; Bertoldo, F; Braga, B; Dorizzi, R; Gatti, D; Locascio, V; Mian, M; Rossini, M; Zamberlan, N, 1994)
"Osteoporosis and osteomalacia have been observed after gastrectomy and appear to be caused by reduced food intake and absorption, and steatorrhea."	2.82	Metabolic bone disorders after gastrectomy: inevitable or preventable? ( Aoyama, T; Atsumi, Y; Rino, Y; Yamada, T; Yukawa, N, 2022)
"Co-treatment with calcitriol (10(-8)M) partially reversed this zoledronate-induced inhibition."	2.80	The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells. ( Edwards, S; Elford, C; Evans, BA; Fogelman, I; Frost, ML; Hampson, G; Ishtiaq, S; Sankaralingam, A, 2015)
"Pamidronate was comparable to alendronate in prevention of early bone loss after kidney transplantation."	2.76	Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation. ( Alasti, M; Beladi Mousavi, SS; Ghorbani, A; Omidvar, B; Shahbazian, H; Shariat Nabavi, SJ, 2011)
"Osteopenia is a common consequence of the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents, due predominantly to glucocorticosteroid therapy."	2.73	Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience. ( Barr, RD; Lethaby, C; Naronha, M; Sala, A; Webber, C; Wiernikowski, J, 2007)
"Alendronate therapy was tolerated well."	2.71	Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study. ( Atkinson, SA; Barr, RD; Guo, CY; Webber, C; Wiernikowski, JT; Wright, M, 2005)
"Osteopenia is a serious medical complication of anorexia nervosa, with no known effective treatment."	2.71	Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. ( Carey, D; Golden, NH; Hertz, S; Iglesias, EA; Jacobson, MS; Meyer, W; Schebendach, J; Shenker, IR, 2005)
"For subjects with postmenopausal osteoporosis, receiver-operating characteristic curve analysis yielded areas under the curve of 0."	2.70	Excretion of sweat and urine pyridinoline crosslinks in healthy controls and subjects with established metabolic bone disease. ( Baylink, D; Drinkwater, B; Farley, S; Kleerekoper, M; Lang, R; Lappe, J; Licata, A; McClung, M; Miller, P; Nattrass, S; Powell, H; Recker, R; Sarno, L; Sarno, M; Schwartz, EN; Tjersland, G; Tucci, JR; Warnick, GR; Wolf, S, 2001)
" The present results indicate that alendronate effectively decreases bone turnover in a dose-related manner and increases lumbar BMD at a dosage of 2."	2.69	A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. ( Fukunaga, M; Inoue, T; Kaneda, K; Kishimoto, H; Kushida, K; Minaguchi, H; Nagata, Y; Nakashima, M; Orimo, H; Shiraki, M; Tomita, A, 1998)
"In women with osteopenia or osteoporosis, 6 years of zoledronic acid reduced clinical fractures (HR, 0."	2.61	Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. ( Brasure, M; Butler, M; Ensrud, KE; Fink, HA; Forte, ML; MacDonald, R; Nelson, VA; Olson, CM; Rosebush, CE; Schousboe, JT; Taylor, BC; Ullman, K; Wilt, TJ, 2019)
" For safety assessment, the incidence of adverse events (AEs) demonstrated no statistical difference between agents and placebo."	2.55	Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis. ( Chen, H; Ma, H; Ma, J; Wang, P; Zhang, H; Zhang, Y; Zhao, X; Zhou, C; Zhu, Y, 2017)
"Osteopenia is a progressive condition that places patients at risk for increased morbidity and mortality if untreated."	2.42	Identifying the osteopenic patient and preventing worsening of the disease. ( Derman, R, 2003)
"Osteopenia has received considerable attention in the past decade."	2.41	Neoplastic and other complications of inflammatory bowel disease. ( Bernstein, CN, 2000)
"Low bone mineral density is encountered in children with acute lymphoblastic leukemia (ALL) before, during, and after treatment."	1.91	Safety and Efficacy of Alendronate to Treat Osteopenia in Children During Therapy for Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of Sequential Outcomes. ( Athale, U; Barr, RD; Cranston, A; Farncombe, T; MacDonald, P; Virdee, M, 2023)
"Osteoporosis is a bone disease leading to bone fracture and affects 200 million women worldwide."	1.91	Quercetin potentiates the anti-osteoporotic effects of alendronate through modulation of autophagy and apoptosis mechanisms in ovariectomy-induced bone loss rat model. ( Azadbakht, O; Behrouj, H; Jafarinia, M; Mousavi, S; Razmjoue, D; Sabaghan, M; Sabetian, S; Savardashtaki, A; Vakili, S; Veisi, A; Zal, F, 2023)
"Hajdu-Cheney syndrome (HCS) is a rare autosomal-dominant disorder primarily characterized by acro-osteolysis and early-onset osteoporosis."	1.48	High Bone Turnover in Mice Carrying a Pathogenic Notch2 Mutation Causing Hajdu-Cheney Syndrome. ( Amling, M; Cornils, K; Fehse, B; Hermans-Borgmeyer, I; Jeschke, A; Oheim, R; Rolvien, T; Schinke, T; Triviai, I; Vollersen, N; Yorgan, TA, 2018)
"Odanacatib (ODN) is a selective and reversible CK inhibitor that inhibits bone loss in preclinical and clinical studies."	1.43	Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate. ( Bellare, JR; Bora, HK; Chattopadhyay, N; Khan, MP; Nagar, GK; Parameswaran, V; Sanyal, S; Shrivastava, P; Singh, AK; Tiwari, MC, 2016)
"Patients with osteopenia showed statistically higher values of osteocyte density than patients with osteoporosis (P < 0."	1.43	Influence of osteoporosis on the osteocyte density of human mandibular bone samples: a controlled histological human study. ( Iezzi, G; Oliveira, PS; Perrotti, V; Piattelli, A; Rodrigues, JA; Shibli, JA, 2016)
"We report a rare association of amniotic bands with osteogenesis imperfecta in a child."	1.42	A rare combination of amniotic constriction band with osteogenesis imperfecta. ( Shah, H; Shah, KH, 2015)
"Alendronate is an antiosteoporotic drug that targets the mevalonate pathway."	1.42	Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density. ( Fu, WZ; Gu, JM; He, JW; Hu, WW; Hu, YQ; Li, M; Liu, YJ; Shao, C; Wang, C; Yue, H; Zhang, H; Zhang, ZL; Zheng, H, 2015)
"Ninety-seven prostate cancer patients treated with androgen deprivation therapy, and severe osteopenia or osteoporosis were retrospectively studied."	1.40	Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy. ( Carles Galceran, J; Celma Domenech, A; Lorente Garcia, D; Morote Robles, J; Placer Santos, J; Planas Morin, J; Regis, L; Salvador Lacambra, C; Trilla Herrera, E, 2014)
"To elucidate the efficacy and adverse events of alendronate (Aldren70) after 12 months of treatment in 50 to 70 years old postmenopausal women."	1.40	A prospective analytical study of the effects and adverse events of alendronate (Aldren70) treatment in Thai postmenopausal women. ( Jaruwangsanti, N; Tienboon, P, 2014)
"Many postmenopausal women have osteopenia, a condition characterized by loss of bone mineral density (BMD) that is not as severe as in osteoporosis."	1.39	Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. ( Fukagawa, M; Inoue, H; Komaba, H; Moriwaki, K; Noto, S; Takahashi, HE; Takiguchi, T; Toujo, T; Yanagisawa, S, 2013)
" Here we disclose the pharmacokinetic profile of JTT-305/MK-5442 and its activity on bone remodeling in ovariectomized (OVX) osteopenic rats."	1.38	Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305/MK-5442 and alendronate in osteopenic ovariectomized rats. ( Cusick, T; Duong, L; Fisher, JE; Glantschnig, H; Karanam, B; Scott, K; Tijerina, M; Wei, N; Zhao, JZ, 2012)
" A potent CatKI, L-006235 (L-235), dosed at 10 mg/kg per day for 27 weeks, significantly decreased LV BMD loss (p < ."	1.37	Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. ( Black, WC; Cusick, TE; Duong, LT; Gauthier, JY; Gentile, MA; Kimmel, DB; Masarachia, PJ; Pennypacker, BL; Samadfam, R; Scott, BB; Smith, SY, 2011)
"When there is osteopenia in the radiographs, the condition is called transient osteoporosis."	1.36	Migrating bone marrow edema syndrome: a cause of recurring knee pain. ( Suresh, SS, 2010)
"Losartan treatment, which lowers TGFβ signaling and restores aortic wall integrity in mice with mild MFS, did not mitigate bone loss in Fbn1(mgR/mgR) mice even though it ameliorated vascular disease."	1.36	Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. ( Carta, L; Cook, JR; Dietz, HC; Lee-Arteaga, S; Nistala, H; Ramirez, F; Rifkin, AN; Rifkin, DB; Siciliano, G; Smaldone, S, 2010)
"A total of 196 consecutive patients treated for distal radius fractures were included in this study."	1.35	Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. ( Ayogu, N; Bouxsein, ML; Chacko, AT; Rozental, TD; Vazquez, MA, 2009)
" The purpose of our study was to verify the effect of laser therapy in combination with bisphosphonate on osteopenic bone structure."	1.35	Effect of low-power gallium-aluminum-arsenium laser therapy (830 nm) in combination with bisphosphonate treatment on osteopenic bone structure: an experimental animal study. ( de Melo Ocarino, N; de Oliveira Pereira, RD; Diniz, JS; do Carmo Magalhães, F; Nicolau, RA; Serakides, R, 2009)
"He was subsequently diagnosed to have osteopenia with a bone mineral density T-score of -1."	1.35	Vertebral fracture in a pilot during centrifuge training: finding of osteopenia. ( Loh, A; Low, R; Ooi, A; Teoh, T, 2008)
"ALN suppressed trabecular bone resorption and endocortical bone erosion and formation and increased periosteal bone formation, while ALF increased the number of osteoblasts and suppressed trabecular bone resorption and markedly increased periosteal and endocortical bone formation."	1.35	Beneficial effects of combined administration of alendronate and alfacalcidol on cancellous bone mass of the tibia in orchidectomized rats: a bone histomorphometry study. ( Iwamoto, J; K Yeh, J; Matsumoto, H; Sato, Y; Takeda, T, 2008)
"For 55 and 60 year old women with osteopenia, treatment with raloxifene compares favorably to interventions accepted as cost-effective."	1.34	Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. ( Johnston, JA; Klein, R; Meadows, ES; Ohsfeldt, RL; Rousculp, MD; Smolen, L, 2007)
"This indicates that osteopenia is not directly related to neuropathic pain behaviors."	1.33	Neuropathy-induced osteopenia in rats is not due to a reduction in weight born on the affected limb. ( Boulet, JM; Bunton, TE; Sellers, R; Walker, K; Whiteside, GT, 2006)
"A history of fracture and a low bone mineral density (BMD) are the strongest predictors of future osteoporotic fracture."	1.33	Influence of fracture history and bone mineral density testing on the treatment of osteoporosis in two non-academic community centers. ( Adachi, JD; Goldsmith, CH; Hamel, ME; Papadimitropoulos, E; Petrie, A; Sebaldt, RJ; Siminoski, K, 2005)
"When alendronate was injected at 3, 4, and 5 weeks, the bone mass increased by 70% and by 166% after 6 and 10 weeks, respectively, in comparison to the untreated control."	1.32	The influence of alendronate on bone formation and resorption in a rat ectopic bone development model. ( Bahar, H; Binderman, I; Kollerman, R; Yaffe, A, 2003)
"Alendronate treatment by itself decreased osteocalcin by day 28 and resulted in a marginal decrease in serum total calcium on day 14."	1.30	Alendronate prevents cyclosporin A-induced osteopenia in the rat. ( Bowman, AR; Epstein, S; Jee, WS; Ma, Y; Sass, DA; Yuan, Z, 1997)
"Ninety six posmenopausal women with osteopenia (WHO classification) in lumbar spine or femoral neck measured by DEXA (table 1) were included in 4 therapeutic groups: Group I (n:19): 17 beta-Estradiol 50 micrograms daily transdermally/medroxiprogesterone 2."	1.30	[Effects on bone mass of oral alendronate, hormone replacement therapy and combined regimes in post-menopausal women: preliminary report on a comparative study]. ( Araujo, GL; Domingo, P; Fajreldines, F; Giglione, F; Noriega, R; Rivoira, MA; Ulla, MR, 1997)
"The aim of the study was to assess the long-term anabolic effect of the parathyroid hormone (PTH) analog SDZ PTS 893 in a dose-response manner, and to determine the ability of the antiresorptive agents estradiol and alendronate to maintain bone mass after withdrawal of SDZ PTS 893."	1.30	Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats. ( Gasser, JA; Mosekilde, LI; Thomsen, JS, 1999)

Research

Studies (122)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Percent Change From Baseline to Week 96 in Lumbar Spine BMD

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	12 (9.84)	18.2507
2000's	45 (36.89)	29.6817
2010's	51 (41.80)	24.3611
2020's	14 (11.48)	2.80

Authors	Studies
Uçar, ZA	1
Sinangil, A	1
Koç, Y	1
Barlas, IS	1
Ecder, ST	1
Akin, EB	1
Tutaworn, T	1
Nieves, JW	1
Wang, Z	1
Levin, JE	1
Yoo, JE	1
Lane, JM	1
MacDonald, P	1
Cranston, A	1
Virdee, M	1
Farncombe, T	1
Athale, U	1
Barr, RD	3
Rajput, S	1
Dutta, A	1
Rajender, S	1
Mithal, A	1
Chattopadhyay, N	2
Mousavi, S	1
Vakili, S	1
Zal, F	1
Savardashtaki, A	1
Jafarinia, M	1
Sabetian, S	1
Razmjoue, D	1
Veisi, A	1
Azadbakht, O	1
Sabaghan, M	1
Behrouj, H	1
Rengel, A	1
Tran, V	1
Toh, LS	1
Sibonga, J	1
Matsumoto, T	1
Jones, J	1
Shapiro, J	1
Lang, T	1
Shackelford, L	1
Smith, SM	1
Young, M	1
Keyak, J	1
Kohri, K	1
Ohshima, H	1
Spector, E	1
LeBlanc, A	1
Kalayjian, RC	1
McComsey, GA	1
Jacobson, DL	2
Lindsey, JC	2
Gordon, C	1
Hazra, R	2
Spiegel, H	1
Ferreira, F	1
Amaral, FR	1
Pagano-Therrien, J	1
Gaur, A	1
George, K	1
Benson, J	1
Siberry, GK	2
Taylor, EA	1
Donnelly, E	1
Yao, X	1
Johnson, ML	1
Amugongo, SK	1
Kimmel, DB	2
Lane, NE	1
Reid, IR	1
Horne, AM	1
Mihov, B	1
Stewart, A	1
Bastin, S	1
Gamble, GD	1
Zhou, J	1
Liu, B	1
Qin, MZ	1
Liu, JP	1
Spiegel, HM	1
Gordon, CM	1
Androjna, C	1
Yee, CS	1
White, CR	1
Waldorff, EI	1
Ryaby, JT	1
Zborowski, M	1
Alliston, T	1
Midura, RJ	1
Rino, Y	2
Aoyama, T	1
Atsumi, Y	2
Yamada, T	1
Yukawa, N	2
Hou, T	1
Liu, Y	2
Kolba, N	1
Guo, D	1
He, H	1
Vollersen, N	1
Hermans-Borgmeyer, I	1
Cornils, K	1
Fehse, B	1
Rolvien, T	1
Triviai, I	1
Jeschke, A	1
Oheim, R	1
Amling, M	1
Schinke, T	1
Yorgan, TA	1
Lange, U	1
Classen, K	1
Müller-Ladner, U	1
Richter, M	1
Karimi Fard, M	1
Aminorroaya, A	1
Kachuei, A	1
Salamat, MR	1
Hadi Alijanvand, M	1
Aminorroaya Yamini, S	1
Karimifar, M	1
Feizi, A	1
Amini, M	1
Wang, WJ	1
Fu, WZ	3
He, JW	3
Wang, C	3
Zhang, ZL	4
Fink, HA	1
MacDonald, R	1
Forte, ML	1
Rosebush, CE	1
Ensrud, KE	3
Schousboe, JT	3
Nelson, VA	1
Ullman, K	1
Butler, M	1
Olson, CM	1
Taylor, BC	1
Brasure, M	1
Wilt, TJ	1
Haider, IT	1
Simonian, N	1
Saini, AS	1
Leung, FM	1
Edwards, WB	1
Schnitzer, TJ	1
Jensen, TW	1
Hansen, MS	1
Hørslev-Petersen, K	1
Hyldstrup, L	1
Abrahamsen, B	1
Langdahl, B	1
Zerahn, B	1
Pødenphant, J	1
Stengaard-Petersen, K	1
Junker, P	1
Østergaard, M	1
Lottenburger, T	1
Ellingsen, T	1
Andersen, LS	1
Hansen, I	1
Skjødt, H	1
Pedersen, JK	1
Lauridsen, UB	1
Svendsen, AJ	1
Tarp, U	1
Lindegaard, H	1
Jurik, AG	1
Vestergaard, A	1
Hetland, ML	1
Patel, V	1
Graves, L	1
Lukert, B	1
Assimos, DG	1
Tsubaki, M	1
Komai, M	1
Itoh, T	1
Imano, M	1
Sakamoto, K	1
Shimaoka, H	1
Takeda, T	4
Ogawa, N	1
Mashimo, K	1
Fujiwara, D	1
Mukai, J	1
Sakaguchi, K	1
Satou, T	1
Nishida, S	1
Planas Morin, J	1
Celma Domenech, A	1
Placer Santos, J	1
Trilla Herrera, E	1
Salvador Lacambra, C	1
Lorente Garcia, D	1
Regis, L	1
Carles Galceran, J	1
Morote Robles, J	1
Tienboon, P	1
Jaruwangsanti, N	1
Zheng, H	2
Zhang, H	2
Yue, H	1
Hu, WW	1
Gu, JM	1
Shao, C	1
Hu, YQ	1
Li, M	4
Liu, YJ	1
Iwamoto, J	4
Uzawa, M	2
Ishtiaq, S	1
Edwards, S	1
Sankaralingam, A	1
Evans, BA	1
Elford, C	1
Frost, ML	1
Fogelman, I	1
Hampson, G	1
Oliveira, PS	1
Rodrigues, JA	1
Shibli, JA	1
Piattelli, A	1
Iezzi, G	1
Perrotti, V	1
Khan, MP	1
Singh, AK	2
Shrivastava, P	1
Tiwari, MC	1
Nagar, GK	1
Bora, HK	1
Parameswaran, V	1
Sanyal, S	1
Bellare, JR	1
Pirbhai, A	1
Rajak, SN	1
Goold, LA	1
Cunneen, TS	1
Wilcsek, G	1
Martin, P	1
Leibovitch, I	1
Selva, D	1
Shah, KH	1
Shah, H	1
Wang, JY	1
Zhou, PR	1
Xu, XJ	1
Ma, DD	1
Xia, WB	2
Jiang, Y	2
Wang, O	1
Xing, XP	1
Veszelyné Kotán, E	1
Mészaros, Á	1
Sato, T	1
Cho, H	1
Yoshikawa, T	1
Yamamoto, N	1
Oshima, T	1
Shiozawa, M	1
Morinaga, S	1
Masuda, M	1
Zhao, X	1
Zhou, C	1
Chen, H	2
Ma, J	1
Zhu, Y	1
Wang, P	1
Zhang, Y	1
Ma, H	1
Diniz, JS	1
Nicolau, RA	1
de Melo Ocarino, N	1
do Carmo Magalhães, F	1
de Oliveira Pereira, RD	1
Serakides, R	1
Farag, N	1
Delbanco, T	1
Strewler, GJ	1
Low, R	1
Teoh, T	1
Loh, A	1
Ooi, A	1
Shomali, T	1
Rezaian, M	1
Rassouli, A	1
Asadi, F	1
Rozental, TD	1
Vazquez, MA	1
Chacko, AT	1
Ayogu, N	1
Bouxsein, ML	1
Planas, J	1
Trilla, E	1
Raventós, C	1
Cecchini, L	1
Orsola, A	1
Salvador, C	1
Placer, J	1
Encabo, G	1
Morote, J	1
Sato, Y	3
Matsumoto, H	2
Sun, P	1
Cai, DH	1
Li, QN	1
Deng, WM	1
He, L	1
Yang, L	1
Migliorati, CA	1
Mattos, K	1
Palazzolo, MJ	1
Pennypacker, BL	1
Duong, LT	1
Cusick, TE	1
Masarachia, PJ	1
Gentile, MA	1
Gauthier, JY	1
Black, WC	1
Scott, BB	1
Samadfam, R	1
Smith, SY	1
Nistala, H	1
Lee-Arteaga, S	1
Carta, L	1
Cook, JR	1
Smaldone, S	1
Siciliano, G	1
Rifkin, AN	1
Dietz, HC	1
Rifkin, DB	1
Ramirez, F	1
Singer, FR	1
Folkesson, J	1
Goldenstein, J	1
Carballido-Gamio, J	1
Kazakia, G	1
Burghardt, AJ	1
Rodriguez, A	1
Krug, R	1
de Papp, AE	1
Link, TM	1
Majumdar, S	1
Suresh, SS	1
Arrabal-Polo, MA	2
Arrabal-Martin, M	2
Zuluaga-Gomez, A	2
Calton, EF	1
Macleay, J	1
Boskey, AL	1
Fitzpatrick, SG	1
Stavropoulos, MF	1
Bowers, LM	1
Neuman, AN	1
Hinkson, DW	1
Green, JG	1
Bhattacharyya, I	1
Cohen, DM	1
Li, X	1
Ominsky, MS	1
Warmington, KS	1
Niu, QT	1
Asuncion, FJ	1
Barrero, M	1
Dwyer, D	1
Grisanti, M	1
Stolina, M	1
Kostenuik, PJ	1
Simonet, WS	1
Paszty, C	1
Ke, HZ	1
Paksu, MS	1
Vurucu, S	1
Karaoglu, A	1
Karacalioglu, AO	1
Polat, A	1
Yesilyurt, O	1
Unay, B	1
Akin, R	1
Yurci, A	1
Kalkan, AO	1
Ozbakir, O	1
Karaman, A	1
Torun, E	1
Kula, M	1
Baskol, M	1
Gursoy, S	1
Yucesoy, M	1
Bayram, F	1
Bartl, R	1
Omidvar, B	1
Ghorbani, A	1
Shahbazian, H	1
Beladi Mousavi, SS	1
Shariat Nabavi, SJ	1
Alasti, M	1
Fisher, JE	1
Scott, K	1
Wei, N	1
Zhao, JZ	1
Cusick, T	1
Tijerina, M	1
Karanam, B	1
Duong, L	1
Glantschnig, H	1
Yang, LJ	1
Shen, FX	1
Zheng, JC	1
Zhang, HL	1
O'Ryan, FS	1
Lo, JC	1
Pytlik, M	1
Cegieła, U	1
Folwarczna, J	1
Nowińska, B	1
Bieglmayer, C	1
Dimai, HP	1
Gasser, RW	1
Kudlacek, S	1
Obermayer-Pietsch, B	1
Woloszczuk, W	1
Zwettler, E	1
Griesmacher, A	1
Seo, SK	1
Yang, HI	1
Lim, KJ	1
Jeon, YE	1
Choi, YS	1
Cho, S	1
Lee, BS	1
Liao, EY	1
Chen, DC	1
Liu, J	1
Tao, TZ	1
Wu, W	1
Lu, YJ	1
Sheng, ZF	1
Lu, CY	1
Meng, GL	1
Xu, L	2
Zhang, WJ	1
Hu, YY	1
Moriwaki, K	1
Komaba, H	1
Noto, S	1
Yanagisawa, S	1
Takiguchi, T	1
Inoue, H	1
Toujo, T	1
Fukagawa, M	1
Takahashi, HE	1
Arranz Caso, JA	1
Flores Ballester, E	1
Ngo Pombe, S	1
López Pizarro, V	1
Dominguez-Mompello, JL	1
Restoy Lozano, A	1
Arias-Santiago, S	1
de Haro-Muñoz, T	1
Lopez-Ruiz, A	1
Orgaz-Molina, J	1
Gonzalez-Torres, S	1
Xia, W	1
Xing, X	1
Yu, W	1
Tian, J	1
Meng, X	1
Zhou, X	1
Andersson, N	2
Surve, VV	2
Lehto-Axtelius, D	2
Ohlsson, C	2
Håkanson, R	2
Andersson, K	2
Ryberg, B	2
Pfeifer, M	1
Begerow, B	1
Pollähne, W	1
Minne, HW	1
Yaffe, A	1
Kollerman, R	1
Bahar, H	1
Binderman, I	1
Derman, R	1
Tosteson, AN	1
Grove, MR	1
Hammond, CS	1
Moncur, MM	1
Ray, GT	1
Hebert, GM	1
Pressman, AR	1
Ettinger, B	1
Howes, O	1
Smith, S	1
Hershman, D	1
Narayanan, R	1
El-Husseini, AA	1
El-Agroudy, AE	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Impact of Oral Alendronate Therapy on Bone Mineral Density in HIV-infected Children and Adolescents With Low Bone Mineral Density[NCT00921557]	Phase 2	52 participants (Actual)	Interventional	2009-11-30	Completed
The Prevalence of Vitamin D Deficiency and Effects of Vitamin D Supplementation in HIV-1 Infected Patients[NCT00306410]	Phase 2	85 participants	Interventional	2006-01-31	Recruiting
Genetic Analysis of Familial Cases of Premature Ovarian Failure[NCT01177891]		110 participants (Actual)	Observational	2010-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Percent change was calculated as (measurement at week 96 - measurement at baseline)/measurement at baseline * 100%. Includes Groups 1A and 1B only. (NCT00921557)
Timeframe: Weeks 0 and 96

Percent Change From Baseline to Week 96 in Whole Body (With Head) BMD

Intervention	Percent change from baseline (Median)
1A: Alendronate/Alendronate	24.9
1B: Alendronate/Placebo	14.8

Percent change was calculated as (measurement at week 96 - measurement at baseline)/measurement at baseline * 100%. Includes Groups 1A and 1B only. (NCT00921557)
Timeframe: Weeks 0 and 96

Percent Change From Week 48 to Week 96 (Group 1B), Week 48 to Week 144 (Group 1B), and Week 96 to 144 (Group 2) in Lumbar Spine BMD

Intervention	Percent change from baseline (Median)
1A: Alendronate/Alendronate	19.6
1B: Alendronate/Placebo	10.3

Percent change was calculated as (measurement at time T2 - measurement at time T1)/measurement at Time T1 * 100%. (NCT00921557)
Timeframe: Weeks 48, 96 and 144

Percent Change From Week 48 to Week 96 (Group 1B), Week 48 to Week 144 (Group 1B), and Week 96 to 144 (Group 2) in Whole Body (With Head) BMD

Intervention	Percent change (Median)
1B: Alendronate/Placebo (48 Week Change)	0.9
2: Placebo/Alendronate (48 Week Change)	2.0
1B: Alendronate/Placebo (96 Week Change)	1.7

Percent change was calculated as (measurement at time T2 - measurement at time T2)/measurement at time T1 * 100%. (NCT00921557)
Timeframe: Weeks 48, 96 and 144

Percentage of Participants Developing New Signs, Symptoms, Hematology or Chemistry Laboratory Values Greater Than or Equal to Grade 3 or New Cases of Jaw Osteonecrosis, Atrial Fibrillation, or Non-healing Fractures

Intervention	Percent change (Median)
1B: Alendronate/Placebo (48 Week Change)	0.8
2: Placebo/Alendronate (48 Week Change)	0.5
1B: Alendronate/Placebo (96 Week Change)	0.9

Signs, symptoms, and laboratory values were graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0 (December 2004). Results for Groups 1A and 1B were combined as both were on alendronate for the first 48 weeks. (NCT00921557)
Timeframe: Week 0 to 48

Change in CD4 Percent From Baseline

Intervention	Participants (Count of Participants)
1: Alendronate	5
2: Placebo	2

Change in percentage of lymphocytes that are CD4 cells calculated as measurement at each time point minus baseline measurement (NCT00921557)
Timeframe: Weeks 0, 48, 96 and 144

Change in Centers for Disease Control (CDC) HIV Disease Category

Intervention	percent of lymphocytes that are CD4 cell (Median)
	Week 48 - Week 0	Week 96 - Week 0	Week 144 - Week 0
1A: Alendronate/Alendronate	0	0	1
1B: Alendronate/Placebo	1	-1	-1
2: Placebo/Alendronate	1	2	-4

Percentage of participants advancing in CDC HIV disease category from baseline throughout study follow-up (NCT00921557)
Timeframe: Weeks 144

Effect of Other Known Bone Mineral Determinants (Age, Gender, Race/Ethnicity, Steroid Use, Depo-Provera, Tenofovir, Pubertal Stage, Bone Age, Vitamin D Status) and Inflammatory Cytokine Levels on Changes in Lumbar Spine BMD

Intervention	Participants (Count of Participants)
	Week 0 to 48	Week 48 to 96	Week 96 to 144
1A: Alendronate/Alendronate	1	0	0
1B: Alendronate/Placebo	0	1	0
2: Placebo/Alendronate	0	0	0

A slope was fit for each participant to their percent change [(measurement at time T - measurement at baseline)/measurement at baseline)*100%] in lumbar spine BMD from baseline. Results represent average changes in lumbar spine BMD over one year. Results are summarized for age, gender, ethnicity, tenofovir use, Tanner stage, bone age and vitamin D level. Only one participant was on steroids and none were using Dep-Provera. Inflammatory cytokine levels were not assayed. Results were combined for Groups 1A and 1B as both were on alendronate for the first 48 weeks. (NCT00921557)
Timeframe: Weeks 0, 24 and 48

Intervention	percentage of baseline (Mean)
	Male	Female	Non-hispanic	Hispanic	11 - < 15 years	15 - < 19 years	>= 19 years	On Tenofovir	Not on Tenofovir	25-OH Vit D<30 ng/ml	25-0H Vit D>=30 ng/ml	Bone age < 15 years	Bone age>=15 years	Tanner stage <= 3	Tanner stage >= 4
1: Alendronate	20.3	25.4	19.4	23.6	37.1	16.5	8.1	24.8	19.9	22.0	22.1	36.0	11.3	33.0	15.4
2: Placebo	6.8	9.4	4.8	7.8	10.6	8.0	1.9	6.8	8.2	6.8	7.8	10.0	5.0	10.6	5.9

A slope was fit for each participant to their percent change [(measurement at time T - measurement at baseline)/measurement at baseline)*100%] in whole body (with head) BMD from baseline. Results represent average changes in whole body (with head) BMD over one year. Results are summarized for age, gender, ethnicity, tenofovir use, Tanner stage, bone age and vitamin D level. Only one participant was on steroids and none were using Dep-Provera. Inflammatory cytokine levels were not assayed. Results were combined for Groups 1A and 1B as both were on alendronate for the first 48 weeks. (NCT00921557)
Timeframe: Weeks 0, 24 and 48

Percent Change From Baseline to Weeks 24 and 48 in Lumbar Spine BMD

Intervention	percentage of baseline (Mean)
	Male	Female	Non-Hispanic	Hispanic	11 - < 15 years	15 - < 19 years	>= 19 years	On tenofovir	Not on tenofovir	25-0H Vit D<30 ng/ml	25-0H Vit D>=30 ng/ml	Bone age < 15 years	Bone age >=15 years	Tanner stage <= 3	Tanner stage >= 4
1: Alendronate	11.4	14.0	9.8	13.9	19.2	10.5	4.7	13.2	11.6	10.6	15.1	19.0	7.7	18.0	9.4
2: Placebo	4.1	8.2	0.3	6.1	8.0	6.5	-0.3	5.0	5.8	5.8	5.2	8.4	2.3	8.0	3.8

Percent change was calculated as (measurement at time T - measurement at baseline)/measurement at baseline * 100%. Results for Groups 1A and 1B combined as both were on alendronate for the first 48 weeks. (NCT00921557)
Timeframe: Weeks 0, 24 and 48

Percent Change From Baseline to Weeks 24 and 48 in Whole Body (With Head) BMD

Intervention	Percent change from baseline (Median)
	Week 24	Week 48
1: Alendronate	14.4	15.9
2: Placebo	5.5	7.1

Percent change was calculated as (measurement at time T - measurement at baseline)/measurement at baseline * 100%. Results for Groups 1A and 1B were combined as both were on alendronate for the first 48 weeks. (NCT00921557)
Timeframe: Weeks 0, 24 and 48

Percent of Participants With HIV-1 RNA <= 400 Copies/ml

Intervention	Percent change from baseline (Median)
	Week 24	Week 48
1: Alendronate	5.5	10.7
2: Placebo	0.3	5.2

Percent calculated as number of participants with HIV-1 RNA <= 400 copies/ml relative to the number of participants with HIV-1 RNA measured at that time point. (NCT00921557)
Timeframe: Weeks 0, 48, 96 and 144

Safety as Measured by the Incidence of New Signs, Symptoms, Hematology or Chemistry Laboratory Values Greater Than or Equal to Grade 3 or New Cases of Jaw Osteonecrosis, Atrial Fibrillation, or Non-healing Fractures

Article	Year
Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis. Frontiers in endocrinology, 2023, Volume: 14 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Deno	2023
Denosumab as a Pharmacological Countermeasure Against Osteopenia in Long Duration Spaceflight. Aerospace medicine and human performance, 2023, May-01, Volume: 94, Issue:5 Topics: Alendronate; Antibodies, Monoclonal; Bone Density Conservation Agents; Bone Diseases, Metabolic; Dip	2023
Metabolic bone disorders after gastrectomy: inevitable or preventable? Surgery today, 2022, Volume: 52, Issue:2 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; F	2022
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Annals of internal medicine, 2019, 07-02, Volume: 171, Issue:1 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonate	2019
Bisphosphonate-Induced Orbital Inflammation: A Case Series and Review. Orbit (Amsterdam, Netherlands), 2015, Volume: 34, Issue:6 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Di	2015
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I]. Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic A	2016
Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis. Medicine, 2017, Volume: 96, Issue:11 Topics: Alendronate; Bayes Theorem; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic	2017
Metabolic bone disease: atypical femoral fractures. Journal of biomechanics, 2011, Jan-11, Volume: 44, Issue:2 Topics: Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biopsy; Bone and Bones	2011
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces]. Medicina clinica, 2012, Dec-15, Volume: 139, Issue:15 Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphon	2012
[Osteoporosis: prevention of bone loss and fractures]. MMW Fortschritte der Medizin, 2002, Nov-28, Volume: 144, Issue:48 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Diseases, Metabolic; Diagnosis, D	2002
Identifying the osteopenic patient and preventing worsening of the disease. Current women's health reports, 2003, Volume: 3, Issue:3 Topics: Alendronate; Body Mass Index; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Calcitonin; Es	2003
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer. Current oncology reports, 2004, Volume: 6, Issue:4 Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation	2004
[Drug treatment of postmenopausal osteoporosis. What's New in 2006]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:10 Pt 2 Topics: Absorptiometry, Photon; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Body Mass Index; B	2006
Interventions for the treatment of decreased bone mineral density associated with HIV infection. The Cochrane database of systematic reviews, 2007, Apr-18, Issue:2 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium, Diet	2007
Bisphosphonates in the treatment of metabolic bone diseases. Annals of medicine, 1993, Volume: 25, Issue:4 Topics: Alendronate; Animals; Bone Diseases, Metabolic; Bone Resorption; Diphosphonates; Female; Humans; Hyp	1993
Neoplastic and other complications of inflammatory bowel disease. Current gastroenterology reports, 2000, Volume: 2, Issue:6 Topics: Alendronate; Bone Density; Bone Diseases, Metabolic; Colitis, Ulcerative; Colorectal Neoplasms; Germ	2000

Article	Year
Resistive exercise in astronauts on prolonged spaceflights provides partial protection against spaceflight-induced bone loss. Bone, 2019, Volume: 128 Topics: Absorptiometry, Photon; Adult; Alendronate; Astronauts; Bone and Bones; Bone Density; Bone Diseases,	2019
Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 08-22, Volume: 71, Issue:5 Topics: Adolescent; Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metab	2020
Zoledronate Slows Weight Loss and Maintains Fat Mass in Osteopenic Older Women: Secondary Analysis of a Randomized Controlled Trial. Calcified tissue international, 2020, Volume: 106, Issue:4 Topics: Age Distribution; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases,	2020
Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study. Orthopaedic surgery, 2020, Volume: 12, Issue:3 Topics: Accidental Falls; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Agents; Bone	2020
Safety and Efficacy of 48 and 96 Weeks of Alendronate in Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection and Low Bone Mineral Density for Age. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 03-15, Volume: 72, Issue:6 Topics: Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; C	2021
Alendronate improves fasting plasma glucose and insulin sensitivity, and decreases insulin resistance in prediabetic osteopenic postmenopausal women: A randomized triple-blind clinical trial. Journal of diabetes investigation, 2019, Volume: 10, Issue:3 Topics: Alendronate; Biomarkers; Blood Glucose; Bone Density Conservation Agents; Bone Diseases, Metabolic;	2019
Open-label clinical trial of alendronate after teriparatide therapy in people with spinal cord injury and low bone mineral density. Spinal cord, 2019, Volume: 57, Issue:10 Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female	2019
Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. Annals of the rheumatic diseases, 2014, Volume: 73, Issue:6 Topics: Adult; Aged; Alendronate; Antirheumatic Agents; Arthritis, Rheumatoid; Betamethasone; Bone Density;	2014
The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells. Cytokine, 2015, Volume: 71, Issue:2 Topics: Alendronate; Angiopoietin-1; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases,	2015
Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures. Yonsei medical journal, 2009, Aug-31, Volume: 50, Issue:4 Topics: Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents;	2009
Longitudinal evaluation of the effects of alendronate on MRI bone microarchitecture in postmenopausal osteopenic women. Bone, 2011, Mar-01, Volume: 48, Issue:3 Topics: Absorptiometry, Photon; Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation A	2011
Osteopenia in children with cerebral palsy can be treated with oral alendronate. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2012, Volume: 28, Issue:2 Topics: Absorptiometry, Photon; Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Bon	2012
Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease. European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:12 Topics: Absorptiometry, Photon; Adult; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agen	2011
Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation. Iranian journal of kidney diseases, 2011, Volume: 5, Issue:6 Topics: Absorptiometry, Photon; Administration, Oral; Adult; Alendronate; Anti-Inflammatory Agents; Bone Den	2011
[Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism]. Zhongguo gu shang = China journal of orthopaedics and traumatology, 2012, Volume: 25, Issue:2 Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female	2012
Changes in serum levels of cartilage oligomeric matrix protein after estrogen and alendronate therapy in postmenopausal women. Gynecologic and obstetric investigation, 2012, Volume: 74, Issue:2 Topics: Aged; Alendronate; Androstenes; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metab	2012
Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis. Menopause (New York, N.Y.), 2013, Volume: 20, Issue:1 Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Re	2013
[Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal]. Zhonghua yi xue za zhi, 2002, Sep-25, Volume: 82, Issue:18 Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density; Bone Diseases, Metabolic; Calcium Carbonate;	2002
Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatric transplantation, 2004, Volume: 8, Issue:4 Topics: Absorptiometry, Photon; Adjuvants, Immunologic; Adolescent; Alendronate; Bone and Bones; Bone Densit	2004
Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis. Journal of bone and mineral metabolism, 2004, Volume: 22, Issue:6 Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Diseases, Metabolic; Chronic Disease; Femal	2004
Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. Journal of acquired immune deficiency syndromes (1999), 2005, Apr-01, Volume: 38, Issue:4 Topics: Absorptiometry, Photon; Adult; Alendronate; Bone Density; Bone Diseases, Metabolic; Calcium; CD4 Lym	2005
Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:6 Topics: Adolescent; Adult; Alendronate; Amenorrhea; Anorexia Nervosa; Body Weight; Bone Density; Bone Diseas	2005
Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2005, Volume: 11, Issue:8 Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic;	2005
Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2005, Volume: 11, Issue:2 Topics: Absorptiometry, Photon; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Alendronate; Bone	2005
Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience. Journal of pediatric hematology/oncology, 2007, Volume: 29, Issue:9 Topics: Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; C	2007
A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. Endocrine journal, 1998, Volume: 45, Issue:2 Topics: Adult; Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density; Bone Diseases, Metabolic;	1998
Excretion of sweat and urine pyridinoline crosslinks in healthy controls and subjects with established metabolic bone disease. Clinical chemistry and laboratory medicine, 2001, Volume: 39, Issue:3 Topics: Adult; Aged; Alendronate; Amino Acids; Area Under Curve; Biomarkers; Bone Diseases, Metabolic; Cross	2001
Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2002, Volume: 2, Issue:1 Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium; Crea	2002

Article	Year
The Effect of Alendronate on Bone Mineral Disorder in Renal Transplant Patients. Transplantation proceedings, 2022, Volume: 54, Issue:3 Topics: Alendronate; Bone Density; Bone Diseases, Metabolic; Calcium; Cholecalciferol; Humans; Kidney Transp	2022
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2023, Volume: 34, Issue:3 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Di	2023
Safety and Efficacy of Alendronate to Treat Osteopenia in Children During Therapy for Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of Sequential Outcomes. Journal of pediatric hematology/oncology, 2023, 05-01, Volume: 45, Issue:4 Topics: Absorptiometry, Photon; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases,	2023
Quercetin potentiates the anti-osteoporotic effects of alendronate through modulation of autophagy and apoptosis mechanisms in ovariectomy-induced bone loss rat model. Molecular biology reports, 2023, Volume: 50, Issue:4 Topics: Alendronate; Animals; Bone Density; Bone Diseases, Metabolic; Female; Humans; Osteoporosis; Ovariect	2023
Bisphosphonates in Perinatally Infected Children and Adolescents With Human Immunodeficiency Virus: Targeting Puberty. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 08-22, Volume: 71, Issue:5 Topics: Adolescent; Alendronate; Bone Density; Bone Diseases, Metabolic; Child; Diphosphonates; HIV; HIV Inf	2020
Sequential Treatment of Estrogen Deficient, Osteopenic Rats with Alendronate, Parathyroid Hormone (1-34), or Raloxifene Alters Cortical Bone Mineral and Matrix Composition. Calcified tissue international, 2020, Volume: 106, Issue:3 Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcification, Phy	2020
A comparison of alendronate to varying magnitude PEMF in mitigating bone loss and altering bone remodeling in skeletally mature osteoporotic rats. Bone, 2021, Volume: 143 Topics: Alendronate; Animals; Bone Diseases, Metabolic; Bone Remodeling; Electromagnetic Fields; Female; Hum	2021
Desalted Duck Egg White Peptides Promote Calcium Uptake and Modulate Bone Formation in the Retinoic Acid-Induced Bone Loss Rat and Caco-2 Cell Model. Nutrients, 2017, May-12, Volume: 9, Issue:5 Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Density; Bone Diseases, Metabolic;	2017
High Bone Turnover in Mice Carrying a Pathogenic Notch2 Mutation Causing Hajdu-Cheney Syndrome. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2018, Volume: 33, Issue:1 Topics: Adult; Alendronate; Animals; Base Sequence; Bone Diseases, Metabolic; Bone Marrow Cells; Bone Remode	2018
Weekly oral bisphosphonates over 2 years prevent bone loss in cardiac transplant patients. Clinical transplantation, 2017, Volume: 31, Issue:11 Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Fol	2017
Association between SOST gene polymorphisms and response to alendronate treatment in postmenopausal Chinese women with low bone mineral density. The pharmacogenomics journal, 2019, Volume: 19, Issue:5 Topics: Adaptor Proteins, Signal Transducing; Aged; Alendronate; Bone Density; Bone Density Conservation Age	2019
Pelvic fractures associated with long-term bisphosphonate therapy - case report. Journal of musculoskeletal & neuronal interactions, 2013, Volume: 13, Issue:2 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonate	2013
Re: effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis. The Journal of urology, 2013, Volume: 190, Issue:2 Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Humans; Hypercalciu	2013
Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation. Journal of biomedical science, 2014, Feb-03, Volume: 21 Topics: Alendronate; Animals; Apoptosis; Bone Diseases, Metabolic; Diphosphonates; Humans; Imidazoles; Macro	2014
Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy. Rheumatology international, 2014, Volume: 34, Issue:10 Topics: Aged; Aged, 80 and over; Alendronate; Androgen Antagonists; Anilides; Antibodies, Monoclonal, Humani	2014
A prospective analytical study of the effects and adverse events of alendronate (Aldren70) treatment in Thai postmenopausal women. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2014, Volume: 97, Issue:6 Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabo	2014
Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density. The pharmacogenomics journal, 2015, Volume: 15, Issue:2 Topics: Aged; Alendronate; Alleles; Asian People; Bone Density; Bone Density Conservation Agents; Bone Disea	2015
Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures. Clinical rheumatology, 2016, Volume: 35, Issue:1 Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Alkaline Phosphatase; Asian People; Bone Density;	2016
Influence of osteoporosis on the osteocyte density of human mandibular bone samples: a controlled histological human study. Clinical oral implants research, 2016, Volume: 27, Issue:3 Topics: Absorptiometry, Photon; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases,	2016
Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2016, Volume: 31, Issue:3 Topics: Alendronate; Animals; Biomechanical Phenomena; Biphenyl Compounds; Bone Density; Bone Diseases, Meta	2016
OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia. Pharmacogenetics and genomics, 2016, Volume: 26, Issue:1 Topics: Alendronate; Bone Density; Bone Diseases, Metabolic; China; Female; Femur Neck; Humans; Lumbar Verte	2016
A rare combination of amniotic constriction band with osteogenesis imperfecta. BMJ case reports, 2015, Nov-11, Volume: 2015 Topics: Alendronate; Amniotic Band Syndrome; Bone Density Conservation Agents; Bone Diseases, Metabolic; Chi	2015
The analysis of DKK1 polymorphisms in relation to skeletal phenotypes and bone response to alendronate treatment in Chinese postmenopausal women. Pharmacogenomics, 2016, Volume: 17, Issue:3 Topics: Alanine Transaminase; Alendronate; Alkaline Phosphatase; Asian People; Biomarkers; Bone Density; Bon	2016
Effectiveness of alendronate for bone disorder after gastrectomy for gastric cancer. Asian journal of surgery, 2017, Volume: 40, Issue:6 Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Diseases, Metabolic; Cholecalciferol;	2017
Effect of low-power gallium-aluminum-arsenium laser therapy (830 nm) in combination with bisphosphonate treatment on osteopenic bone structure: an experimental animal study. Lasers in medical science, 2009, Volume: 24, Issue:3 Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Diseases, Metabolic; Combined Modality	2009
Update: A 64-year-old woman with primary hyperparathyroidism. JAMA, 2008, Nov-05, Volume: 300, Issue:17 Topics: Adenoma; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Disease Progressio	2008
Vertebral fracture in a pilot during centrifuge training: finding of osteopenia. Aviation, space, and environmental medicine, 2008, Volume: 79, Issue:11 Topics: Adult; Aerospace Medicine; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic;	2008
Effect of eicosapentaenoic acid on bone changes due to methylprednisolone in rats. Basic & clinical pharmacology & toxicology, 2009, Volume: 105, Issue:1 Topics: Alendronate; Animals; Biomarkers; Body Weight; Bone and Bones; Bone Density Conservation Agents; Bon	2009
Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. The Journal of hand surgery, 2009, Volume: 34, Issue:4 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bo	2009
Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU international, 2009, Volume: 104, Issue:11 Topics: Absorptiometry, Photon; Aged; Alendronate; Androgen Antagonists; Bone Density; Bone Density Conserva	2009
Effects of alendronate and strontium ranelate on cancellous and cortical bone mass in glucocorticoid-treated adult rats. Calcified tissue international, 2010, Volume: 86, Issue:6 Topics: Absorptiometry, Photon; Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservatio	2010
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care. Journal of the American Dental Association (1939), 2010, Volume: 141, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conser	2010
Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2011, Volume: 26, Issue:2 Topics: Alendronate; Animals; Biphenyl Compounds; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bo	2011
Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. Human molecular genetics, 2010, Dec-15, Volume: 19, Issue:24 Topics: Alendronate; Animals; Aorta; Aortic Aneurysm; Bone Diseases, Metabolic; Bone Morphogenetic Proteins;	2010
Migrating bone marrow edema syndrome: a cause of recurring knee pain. Acta orthopaedica et traumatologica turcica, 2010, Volume: 44, Issue:4 Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Bone Density; Bone Density Conservation Agents	2010
[Alendronate and resorptive hypercalciuria]. Medicina clinica, 2011, Sep-17, Volume: 137, Issue:7 Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; C	2011
Fourier transform infrared imaging analysis of cancellous bone in alendronate- and raloxifene-treated osteopenic sheep. Cells, tissues, organs, 2011, Volume: 194, Issue:2-4 Topics: Alendronate; Animals; Bone and Bones; Bone Diseases, Metabolic; Raloxifene Hydrochloride; Sheep; Spe	2011
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:2 Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age	2012
Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology, 2011, Volume: 152, Issue:9 Topics: Acid Phosphatase; Alendronate; Animals; Antibodies, Monoclonal; Bone and Bones; Bone Density; Bone D	2011
[Inflammation of the jaws during treatment with bisphosphonates]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:41 Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseas	2011
Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305/MK-5442 and alendronate in osteopenic ovariectomized rats. Bone, 2012, Volume: 50, Issue:6 Topics: Alendronate; Animals; Benzoates; Bone Density; Bone Density Conservation Agents; Bone Diseases, Meta	2012
Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:8 Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antirheumatic Age	2012
Proton pump (H+/K+-ATPase) inhibitors weaken the protective effect of alendronate on bone mechanical properties in estrogen-deficient rats. Pharmacological reports : PR, 2012, Volume: 64, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alendronate; Animals; Bone and Bones; Bone Density; Bone De	2012
Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group. Wiener medizinische Wochenschrift (1946), 2012, Volume: 162, Issue:21-22 Topics: Absorptiometry, Photon; Alendronate; Algorithms; Austria; Biomarkers; Bone Density; Bone Density Con	2012
Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2013, Volume: 28, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Diseases, Metabolic; Cost-Benefit An	2013
Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis. Urology, 2013, Volume: 81, Issue:4 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Fema	2013
Drug-induced prevention of gastrectomy- and ovariectomy-induced osteopaenia in the young female rat. The Journal of endocrinology, 2002, Volume: 175, Issue:3 Topics: Alendronate; Analysis of Variance; Animals; Biomarkers; Bone Density; Bone Diseases, Metabolic; Estr	2002
The influence of alendronate on bone formation and resorption in a rat ectopic bone development model. Journal of periodontology, 2003, Volume: 74, Issue:1 Topics: Alendronate; Analysis of Variance; Animals; Bone Density; Bone Diseases, Metabolic; Bone Marrow; Bon	2003
Early discontinuation of treatment for osteoporosis. The American journal of medicine, 2003, Aug-15, Volume: 115, Issue:3 Topics: Alendronate; Bone Diseases, Metabolic; Breast Neoplasms; California; Cohort Studies; Estrogen Replac	2003
Alendronic acid for antipsychotic-related osteopenia. The American journal of psychiatry, 2004, Volume: 161, Issue:4 Topics: Alendronate; Antipsychotic Agents; Bone Diseases, Metabolic; Female; Haloperidol; Humans; Middle Age	2004
Pharmacological treatment of osteopenia induced by gastrectomy or ovariectomy in young female rats. Acta orthopaedica Scandinavica, 2004, Volume: 75, Issue:2 Topics: Alendronate; Animals; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Estrogens; Female; Gas	2004
Influence of fracture history and bone mineral density testing on the treatment of osteoporosis in two non-academic community centers. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:2 Topics: Adult; Age Factors; Alendronate; Bone Density; Bone Diseases, Metabolic; Calcium, Dietary; Estrogens	2005
Summaries for patients. Cost-effectiveness of alendronate in postmenopausal women with low bone mass without osteoporosis or previous fracture. Annals of internal medicine, 2005, May-03, Volume: 142, Issue:9 Topics: Aged; Alendronate; Bone Density; Bone Diseases, Metabolic; Cost-Benefit Analysis; Female; Fractures,	2005
Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Annals of internal medicine, 2005, May-03, Volume: 142, Issue:9 Topics: Aged; Alendronate; Bone Density; Bone Diseases, Metabolic; Cost-Benefit Analysis; Female; Fractures,	2005
Osteopenia: to treat or not to treat? Annals of internal medicine, 2005, May-03, Volume: 142, Issue:9 Topics: Aged; Alendronate; Bone Diseases, Metabolic; Cost-Benefit Analysis; Female; Fractures, Bone; Humans;	2005
Neuropathy-induced osteopenia in rats is not due to a reduction in weight born on the affected limb. Bone, 2006, Volume: 38, Issue:3 Topics: Alendronate; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Diseases, Me	2006
Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis? Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2005, Volume: 27, Issue:8 Topics: Aged; Alendronate; Analysis of Variance; Bone Density; Bone Density Conservation Agents; Bone Diseas	2005
Rethinking early bone-loss treatment. Mayo Clinic health letter (English ed.), 2005, Volume: 23, Issue:9 Topics: Alendronate; Bone Diseases, Metabolic; Female; Humans	2005
Comparative therapeutic effects of alendronate and alfacalcidol on cancellous and cortical bone mass and mechanical properties in ovariectomized osteopenic rats. Journal of nutritional science and vitaminology, 2006, Volume: 52, Issue:1 Topics: Alendronate; Amino Acids; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Disea	2006
Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2007, Volume: 18, Issue:2 Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone and Bones; Bone Density	2007
The effect of pregnancy on pre-existing osteopenia: a case report. Archives of gynecology and obstetrics, 2007, Volume: 276, Issue:2 Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female	2007
Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2007, Volume: 18, Issue:10 Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Glomerulosclerosis, Focal S	2007
[Questions and answers about bisphosphonates]. Presse medicale (Paris, France : 1983), 2007, Volume: 36, Issue:3 Pt 1 Topics: Administration, Oral; Age Factors; Alendronate; Bone Density; Bone Density Conservation Agents; Bone	2007
Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC women's health, 2007, Apr-17, Volume: 7 Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Cos	2007
Onion decreases the ovariectomy-induced osteopenia in young adult rats. Bone, 2008, Volume: 42, Issue:6 Topics: Alendronate; Animals; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, M	2008
Beneficial effects of combined administration of alendronate and alfacalcidol on cancellous bone mass of the tibia in orchidectomized rats: a bone histomorphometry study. Journal of nutritional science and vitaminology, 2008, Volume: 54, Issue:1 Topics: Alendronate; Animals; Body Weight; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone	2008
Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2008, Volume: 14, Issue:3 Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Cons	2008
Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. Bone and mineral, 1994, Volume: 25, Issue:2 Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Diseases, Metabolic; Bone Resorption; Calcium; Diphosp	1994
Effects of aminohydroxybutane bisphosphonate on bone growth when administered after hind-limb bone loss in tail-suspended rats. The Journal of pharmacology and experimental therapeutics, 1993, Volume: 267, Issue:1 Topics: Alendronate; Animals; Bone Density; Bone Development; Bone Diseases, Metabolic; Diphosphonates; Hind	1993
The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats. Calcified tissue international, 1993, Volume: 53, Issue:4 Topics: Alendronate; Animals; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Diphosphonates; Di	1993
Alendronate prevents cyclosporin A-induced osteopenia in the rat. Bone, 1997, Volume: 21, Issue:1 Topics: Administration, Oral; Alendronate; Analysis of Variance; Animals; Body Weight; Bone Diseases, Metabo	1997
[Effects on bone mass of oral alendronate, hormone replacement therapy and combined regimes in post-menopausal women: preliminary report on a comparative study]. Medicina, 1997, Volume: 57 Suppl 1 Topics: Aged; Alendronate; Analysis of Variance; Bone Density; Bone Diseases, Metabolic; Drug Combinations;	1997
Alendronate in the treatment of osteoporosis. Aging (Milan, Italy), 1998, Volume: 10, Issue:2 Topics: Aged; Alendronate; Bone Density; Bone Diseases, Metabolic; Calcitonin; Estrogen Replacement Therapy;	1998
Hypocalcemia associated with alendronate. Annals of internal medicine, 1999, Feb-16, Volume: 130, Issue:4 Pt 1 Topics: Aged; Alendronate; Bone Diseases, Metabolic; Female; Humans; Hypocalcemia; Hypoparathyroidism	1999
Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats. Bone, 1999, Volume: 25, Issue:5 Topics: Aging; Alendronate; Animals; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Resorption	1999
Do different aminobisphosphonates have similar preventive effect on experimental thyroid hormone-induced osteopenia in rats? Calcified tissue international, 2001, Volume: 69, Issue:5 Topics: Alendronate; Animals; Body Weight; Bone Diseases, Metabolic; Diphosphonates; Female; Pamidronate; Ra	2001
Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1992, Volume: 7, Issue:12 Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Diseases, Metabolic; Diphosphona	1992
Aminohydroxybutane bisphosphonate inhibits bone loss due to immobilization in rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1990, Volume: 5, Issue:3 Topics: Alendronate; Animals; Bone Density; Bone Diseases, Metabolic; Denervation; Diphosphonates; Immobiliz	1990

alendronate and Low Bone Density